News

NICE is told to break its close links with drug industry

BMJ 2003; 327 doi: 10.1136/bmj.327.7416.637 (Published 18 September 2003)
Cite this as: BMJ 2003;327:637.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Zosia Kmietowicz
  1. London

    The National Institute for Clinical Excellence (NICE) has been advised by an independent review to break its close links with the drug industry and to make its processes more transparent.


    Embedded Image

    Kees de Joncheere, WHO's regional adviser for health technology and pharmaceuticals (left) and Professor Michael Rawlins, NICE chairman

    Credit: WHO

    Experts from the World Health Organization who carried out the review have advised NICE that, to avoid any possible bias, pharmaceutical physicians should not be members of committees that make judgments on particular drugs …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular